Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04507204 · ClinicalTrials.gov registry record · Phase 4
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 4 study, sponsored by Purdue Pharma.
- Terminated
- Registry status
- Phase 4
- Development phase
- 267
- Enrollment target
NCT04507204 is a Phase 4 study that was terminated before completion, run by Purdue Pharma. The registered enrollment target is 267 participants.
The verdict
NCT04507204, a Phase 4 study, was terminated before completion, sponsored by Purdue Pharma.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 267 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over time.
Interventions
- DRUG Concerta
- DRUG Adhansia XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04507204
The ClinicalTrials.gov registry entry for NCT04507204 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Concerta is the first listed.
NCT04507204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04507204 about?
NCT04507204 is a clinical study titled "Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)". The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over time.
What is the current status of trial NCT04507204?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 267 participants. The study started on 2020-07-30. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04507204?
The interventions under investigation include: Concerta (DRUG), Adhansia XR (DRUG).
Who is sponsoring clinical trial NCT04507204?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.